ANI Pharmaceuticals (NASDAQ:ANIP) Announces Quarterly Earnings Results, Beats Estimates By $0.52 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52, FiscalAI reports. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The business had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. During the same period in the previous year, the company posted $2.04 earnings per share. The business’s revenue for the quarter was up 27.6% on a year-over-year basis.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported third-quarter revenue of $290.8 million, up 28% year over year, and adjusted EBITDA of $83.3 million, up 40%; adjusted diluted EPS rose to $2.70. Generics revenue increased 11% to $104.5 million, while ILUVIEN revenue grew 34% to $22.3 million.
• Cortrophin Gel revenue was $138.7 million, below expectations, as specialty-pharmacy capacity constraints and slower onboarding at new gout prescribers delayed conversion of cases to patients on therapy. ANI cut 2026 Cortrophin guidance to $480 million–$500 million from $520 million–$540 million, while citing strong demand and steps to improve fulfillment.
• ANI updated 2026 total revenue guidance to $1.085 billion–$1.125 billion and raised adjusted EBITDA guidance to $290 million–$300 million and adjusted EPS guidance to $9.37–$9.71; ILUVIEN guidance also increased to $80 million–$85 million. The company said strong profitability and favorable product mix support the higher earnings outlook.
• ANI announced an all-cash offer for Egetis Therapeutics valuing its equity at $560 million, adding EMCITATE, the first approved treatment for MCT8 deficiency, to its rare-disease portfolio. ANI sees peak annual sales potential above $300 million and expects to leverage its commercial infrastructure, though the deal is expected to dilute adjusted EPS in year one and raise pro forma net leverage to about 2.7x.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded down $0.45 during mid-day trading on Friday, reaching $69.17. The company had a trading volume of 194,760 shares, compared to its average volume of 382,030. ANI Pharmaceuticals has a 1 year low of $68.51 and a 1 year high of $95.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a market capitalization of $1.59 billion, a P/E ratio of 14.90, a P/E/G ratio of 2.31 and a beta of 0.45. The stock’s 50-day simple moving average is $72.65 and its 200-day simple moving average is $77.41.

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $73.59, for a total value of $36,795.00. Following the sale, the vice president owned 73,424 shares in the company, valued at $5,403,272.16. This represents a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer directly owned 333,689 shares of the company’s stock, valued at $23,988,902.21. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 30,412 shares of company stock worth $2,220,970 over the last quarter. Insiders own 8.10% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: ANI reported adjusted earnings of $2.70 per share versus consensus of about $2.18, while revenue of $290.78 million exceeded estimates of $280.59 million. Revenue increased 27.6% year over year, and EPS rose from $2.04. The earnings beat and growth are supportive of the stock. ANI Pharmaceuticals Q3 2026 results
• Positive Sentiment: Proposed Egetis acquisition would expand rare-disease business: ANI made a recommended public offer valued at approximately SEK 5.6 billion (about $560 million) for Swedish biotech Egetis Therapeutics. The deal could broaden ANI’s rare-disease portfolio and growth opportunities. ANI Pharmaceuticals Egetis offer
• Neutral Sentiment: Acquisition adds execution and financial considerations: The offer’s strategic rationale is clear, but investors will weigh its cost, funding implications and integration alongside the potential benefits. ANI offer to acquire Egetis
• Negative Sentiment: Shares remain near their one-year low: That weak trading context indicates investor caution persists despite the earnings beat; the acquisition’s cost and execution may be among the issues investors are considering.

Analyst Ratings Changes

A number of brokerages have issued reports on ANIP. Canaccord Genuity Group decreased their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price target for the company. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Oppenheimer initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective for the company. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $100.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.